Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ixazomib · Ninlaro, MLN9708

Small molecule · Inhibitor of proteasome beta 5 subunit (20S proteasome) (PSMB5) · developed by Takeda Pharms Usa

Approved FDA, Nov 2015
TAK Developer
2 Registered trials

What is Ixazomib?

Ixazomib is an orally bioavailable proteasome inhibitor that reversibly binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome, leading to accumulation of misfolded proteins and induction of apoptosis. It is used in combination with lenalidomide and dexamethasone for multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ninlaro, MLN9708, MLN-2238
Drug type
Small molecule
Targets
proteasome beta 5 subunit (20S proteasome) (PSMB5)
Mechanism
Inhibitor of proteasome beta 5 subunit (20S proteasome) (PSMB5)
Pathways
apoptosis, protein degradation (ubiquitin-proteasome)
Therapy area
Immunology, Infectious disease, Renal & urology
Developer
Takeda Pharms Usa (TAK)
FDA status
Approved as Ninlaro (November 20, 2015), NDA208462 · FDA label
UNII
71050168A2

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 11, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07881809 Phase 2 HIV (Human Immunodeficiency Virus) Not yet recruiting TAK
NCT02542657 Phase 1/2 Myeloma Completed TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV (Human Immunodeficiency Virus)Myeloma

More from Takeda Pharms Usa

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Ixazomib

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.